#136289
Re: Farmas USA
PFE
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
- Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion
- Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00
- Expect Full-Year 2025 Adjusted(2) Diluted EPS Operational(3) Growth of 10% to 18% from the Midpoint of 2024 Guidance After Adjusting for 2024 Non-Recurring Items(4)
- Achieved Goal of $4.0 Billion in Net Cost Savings Through 2024 and Anticipate an Additional $500 Million in Savings in 2025 from Ongoing Cost Realignment Program
- First Phase of Manufacturing Optimization Program On Track to Deliver Initial Net Cost Savings in the Latter Part of 2025, Toward Goal of Improving Gross Margin Performance
![](https://d31dn7nfpuwjnm.cloudfront.net/images/valoraciones/0065/1170/cash_maker_foro.gif?1734444821)
Trimestral de 25 años
![](https://d31dn7nfpuwjnm.cloudfront.net/images/valoraciones/0065/1175/PFE-Quarterly_foro.png?1734445381)